Receptor News and Research

RSS

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

29 Nov 2021

New phenotype of LRP6 mutation reported for the first time in patients with tooth agenesis

A group led by Prof. Han Dong of Peking University School of Stomatology reported for the first time hand preaxial polydactyly in patients with tooth agenesis carrying a previously unknown mutation of low-density lipoprotein receptor-related protein 6 (LRP6).

29 Nov 2021

An update of what is currently known about Omicron

On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO's Technical Advisory Group on Virus Evolution (TAG-VE).

29 Nov 2021

Heart failure patients may benefit from common type 2 diabetes drug

Dapagliflozin, a drug commonly used to treat type 2 diabetes, improved symptoms and physical limitations in patients with heart failure with preserved ejection fraction, according to clinical trial results published in Nature Medicine.

29 Nov 2021

Extended host range for SARS-CoV-2 variants of concern

Researchers used viral pseudotyping to examine whether variants of concern had different host ACE2 receptor usage patterns.

29 Nov 2021

Immunity found 6 months after SARS-CoV-2 infection in children

A new study suggests that infection-induced antibodies persist, providing protection for at least six months.

29 Nov 2021

Do we need COVID-19 vaccine boosters?

An article published recently in the Journal of Virology explored the science behind COVID-19 vaccine boosters.

29 Nov 2021

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Researchers investigated the immunogenicity of a novel adjuvant comprised of a modified porous silicon microparticle for the SARS-CoV-2 S protein RBD subunit vaccine.

29 Nov 2021

Study suggests making COVID vaccines based on Mu variant

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant (B.1.621, B.1.621.1) has been tagged as a Variant Being Monitored (VBM), and as of August 30, 2021, it had been detected in 39 countries.

28 Nov 2021

Identifying the spread of novel B.1.1.523 SARS-CoV-2

In their recent study, researchers from Lithuania have reported the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant lineage B.1.1.523 containing a set of mutations associated with immune escape, including deletion 156_158del, substitution E484K and S494P in Spike (S) protein.

28 Nov 2021

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

A recent research paper by scientists from Denmark reveals that circulating plasmacytoid dendritic cells may be a potential therapeutic target to maintain desired levels of an antiviral compound known as interferon, allowing for the mitigation of coronavirus disease (COVID-19) severity. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

28 Nov 2021

An analysis of SARS-CoV-2 breakthrough infections by variant and vaccine

Researchers compared the distribution of SARS-CoV-2 genotypes to the prevalence of SARS-CoV-2 variants.

28 Nov 2021

The introduction and rapid spread of SARS-CoV-2 Gamma in Venezuela

Researchers from the Instituto Venezolano de Investigaciones Científica investigate the introduction of one of the VOCs into Venezuela.

28 Nov 2021

SARS-CoV-2 Omicron variant: What we know so far

On November 24, 2021, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant was first reported to the World Health Organization (WHO) from South Africa.

28 Nov 2021

Efficacy and safety of an RBD-based recombinant protein COVID-19 vaccine

A study developed a protein-based subunit vaccine, PHH-1V, that consisted of a recombinant RBD fusion heterodimer of the alpha) and beta variants of SARS-CoV-2.

26 Nov 2021

SARS-CoV-2 vaccine based on vesicular stomatitis virus exhibits high neutralizing efficacy against variants

Scientists have tested the efficacy of BriLife®-vaccinated human sera in neutralizing more infectious and probably more virulent SARS-CoV-2 variants.

26 Nov 2021

A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection

In a literature review article published in the Journal of Community Hospital Internal Medicine Perspectives, authors from the US performed a thorough investigation of previous studies and case reports of SARS-CoV-2 reinfection. This review discusses the role of natural immunity, vaccines, and SARS-CoV-2 variants in reinfection.

25 Nov 2021